 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | AIR DNAse (alidornase alfa) / Protalix
Journal: Oral inhalation for delivery of proteins and peptides to the lungs. (Pubmed Central) - May 8, 2021
While development of various biologics has been halted or has shown little effects, AIR DNase, alpha1-proteinase inhibitor, recombinant neuraminidase, and heparin are currently being evaluated in phase III trials. Several biologics are being tested for the treatment of coronavirus disease (COVID)-19, and it is expected that these trials will lead to improvements in pulmonary delivery of biologics.
- | AIR DNAse (alidornase alfa) / SarcoMed
Trial completion, Trial primary completion date: Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers (clinicaltrials.gov) - May 18, 2016
P1, N=18, Completed, Sponsor: Protalix
Several biologics are being tested for the treatment of coronavirus disease (COVID)-19, and it is expected that these trials will lead to improvements in pulmonary delivery of biologics. Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Feb 2016
- | AIR DNAse (alidornase alfa) / SarcoMed
Enrollment open: Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase (clinicaltrials.gov) - May 18, 2016
P2, N=15, Recruiting, Sponsor: Protalix
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Feb 2016 Not yet recruiting --> Recruiting
- AIR DNAse (alidornase alfa) / SarcoMed
Trial primary completion date: Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers (clinicaltrials.gov) - Apr 19, 2016
P1, N=18, Recruiting, Sponsor: Protalix
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2016 --> Dec 2016
- | AIR DNAse (alidornase alfa) / SarcoMed
New P2 trial: Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase (clinicaltrials.gov) - Mar 29, 2016
P2, N=15, Not yet recruiting, Sponsor: Protalix
- AIR DNAse (alidornase alfa) / SarcoMed
Enrollment open: Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers (clinicaltrials.gov) - Mar 1, 2016
P1, N=18, Recruiting, Sponsor: Protalix
Trial primary completion date: Feb 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- | AIR DNAse (alidornase alfa) / SarcoMed
New P1 trial: Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers (clinicaltrials.gov) - Nov 16, 2015
P1, N=18, Not yet recruiting, Sponsor: Protalix